Open

MODERN

The study is enrolling participants to see if the disitamab vedotin works to treat bladder cancer when used alone or when it is used in combination with pembrolizumab.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

The study includes blood draws, CT and/or MRI's, ECG's and completion of questionnaires.

Incentives

Possible travel reimbursement.

In-person visits:
More than 10.

Total length of participation:
Up to 3 years.

Looking for Specific Volunteers

Able to participate:

You are at least 18 years old.
You have been diagnosed with bladder cancer
Your bladder cancer has spread to nearby tissue or other parts of the body.

Not eligible if:

You have received antitumor treatment (chemotherapy, radiotherapy, targeted therapy, etc.)
You have participated in another clinical study within 2 weeks prior to the start of the study.
Known hypersensitivity to disitamab vedotin or pembrolizumab.
You have an acute, chronic or symptomatic infection.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Matthew Milowsky
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Bladder)

IRB Number

24-0407

ClinicalTrials.gov

NCT04879329

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.